<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221919</url>
  </required_header>
  <id_info>
    <org_study_id>HR management</org_study_id>
    <nct_id>NCT04221919</nct_id>
  </id_info>
  <brief_title>Different β -Blockers in STEMI and Primary PCI</brief_title>
  <official_title>Different β -Blockers in Patients With ST-segment Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carvedilol, target dose: 50 mg daily; Bisoprolol, target dose: 10 mg daily; Metoprolol
      tartrate, target dose: 150 mg daily; Metroprolol succinate, target dose: 200 mg daily
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will investigate the efficacy and safety of different β -blockers, as well
      as heart rate variability, in STEMI patients undergoing primary PCI.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LVEDV from baseline</measure>
    <time_frame>1 to 5 years</time_frame>
    <description>The primary outcome of this study will be the change from baseline in left ventricular end diastolic volume (LVEDV) post-PCI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiovascular events (MACE)</measure>
    <time_frame>1 to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Primary PCI</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bisoprolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol tartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>β -Blockers</intervention_name>
    <description>Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate</description>
    <arm_group_label>Bisoprolol</arm_group_label>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <arm_group_label>Metoprolol tartrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted for primary PCI for STEMI involving the LAD within 12 hours of onset of
             symptoms. STEMI will be defined as typical ECG changes (ST segment elevation ≥2mm in 2
             or more precordial leads) associated with acute chest pain or an elevation of cardiac
             enzymes;

          -  Age ≥18 years;

          -  Informed consent from patient or next of kin.

        Exclusion Criteria:

          -  Nonischaemic Cardiomyopathy;

          -  Cardiac surgery planed in the 6 months;

          -  Mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute
             severe mitral regurgitation);

          -  Renal or hepatic failure;

          -  Malignancy, HIV, or central nervous system disorder;

          -  Cardiopulmonary resuscitation &gt;15 min and compromised level of consciousness;

          -  Cardiogenic shock;

          -  Current participation in any research study involving investigational drugs or
             devices;

          -  No written consensus;

          -  Previous myocardial infarction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 5, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Pan-Pan Hao</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

